Collectively, our findings reveal that the suppression of DPP4 expression in adipose tissue and DPP4 activity in plasma with nondiabetic plasma-treated SVFs may ultimately attenuate glucose intolerance and insulin resistance in diabetes. The gene discussed is DPP4; the disease is Glucose intolerance.